An HHV-8 Positive HIV Negative Multicentric Castleman’s Disease, who Responded well to Rituximab Alone

Title:An HHV-8 Positive HIV Negative Multicentric Castleman’s Disease, who Responded well to Rituximab Alone

Volume: 20 Issue: 1

Author(s): Dimitris Kounatidis, Dimitra Rontogianni, Dimitrios Sampaziotis, Maria Vardaka, Chara Giatra, Christodoulos Dolapsakis, Evangelia Margellou and Natalia G. Vallianou*

Affiliation:

• Department of Internal Medicine, Evangelismos General Hospital, Athens,Greece

Keywords: Multicentric castleman disease, HHV-8 positive, HIV negative, rituximab, lymphoproliferative, cytokine.

Abstract:

Background: Multicentric Castleman Disease (MCD) presents with enlarged lymph nodes in multiple regions and systemic inflammatory symptoms, due to the dysregulation of cytokines, most commonly interleukin-6 (IL-6). Human herpes virus-8 (HHV-8) is strongly related to MCD (HHV-8-associated MCD) and is being implicated in cytokine dysregulation in patients, the majority of whom are HIV positive or immunosuppressed. Preferred treatment of HHV-8- associated MCD depends on the presence or not of concurrent Kaposi sarcoma and on whether the patient has life-threatening organ failure or poor performance status thought to be related to HHV- 8-associated MCD.

Case Presentation: Herein, we describe a female patient with HHV-8 positive, HIV negative MCD, who responded well to the administration of rituximab once weekly for four weeks alone for three cycles.

Conclusion: HHV-8 positive, HIV negative MCD treatment modalities are only anecdotal due to the rarity of this form of MCD. Administration of rituximab alone seems to be beneficial among patients with good performance status and the absence of life-threatening organ failure in cases of HHV-8 positive, HIV negative MCD.

Cite this article as:

Kounatidis Dimitris, Rontogianni Dimitra, Sampaziotis Dimitrios, Vardaka Maria, Giatra Chara, Dolapsakis Christodoulos, Margellou Evangelia and Vallianou G. Natalia*, An HHV-8 Positive HIV Negative Multicentric Castleman’s Disease, who Responded well to Rituximab Alone, Cardiovascular & Hematological Disorders-Drug Targets 2020; 20 (1) . https://dx.doi.org/10.2174/1871529X19666190227185318